# US 2020/0297781 A1 · Composition, A Treatment Method and An Application Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0297781 A1
- Document ID: US20200297781A1
- Status: Published application
- Kind: A1
- Application number: 16/841,949
- Filed: 2020-04-07
- Published: 2020-09-24
- Earliest claimed: 2017-01-20
- Assignees: Blue Elegant Biotech Co., Ltd.
- Applicants: Blue Elegant Biotech Co., Ltd.
- Inventors: Xiaoping Chen; Li Qin
- Web page: https://patentgrep.com/patent/US20200297781A1

## CPC

- A61K 35/68: Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
- A61K 39/015: Hemosporidia antigens, e.g. Plasmodium antigens
- A61K 40/10: characterised by the cell type used
- A61K 40/42: Cancer antigens
- A61K 40/438: {Hemosporidia antigens, e.g. Plasmodium antigens}
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61K 2039/577: {tolerising response}
- A61K 2039/585: {wherein the target is cancer}
- A61K 2039/804: {Blood cells [leukemia, lymphoma]}
- A61K 2039/812: {Breast}
- A61K 2039/82: {Colon}
- A61K 2039/86: {Lung}
- A61K 2039/876: {Skin, melanoma}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- A61K 2239/49: Breast
- A61K 2239/50: Colon
- A61K 2239/53: Liver
- A61K 2239/55: Lung
- A61K 2239/57: Skin; melanoma
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to the field of treatment of tumor, and especially to a composition comprising a plasmodium, a treatment method and an application thereof. The composition of the present invention has therapeutic effects on colorectal carcinoma, lung carcinoma, breast carcinoma, gastric carcinoma and hepatic carcinoma etc., can inhibit the growth of tumor and prolong the life of the tumor patients, whereas has no therapeutic effect on melanoma and lymphoma; meanwhile, the present invention describes that the long-term plasmodium infection has better therapeutic effect on tumors, and the plasmodium immunotherapy of the present invention does not take the fever time as a course standard when treating tumors, but should be used to extend the duration of plasmodium infection as much as possible until the progression of tumors can be controlled under the premise of protecting the organ functions and life safety of the patients.

## Claims

### Claim 1

A method for treating a solid tumor, comprising
a) administering to a patient in need thereof a therapeutically effective amount of a composition comprising a plasmodium, wherein the plasmodium is any one or a mixture of at least two of Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale or Plasmodium knowlesi; and
b) allowing a long-term plasmodium infection to establish in the patient, wherein the long-term plasmodium infection is a chronic malarial infection with an infection time course of more than 6-8 weeks,
wherein the solid tumor is selected from the group consisting of gastric carcinoma, colon carcinoma and breast carcinoma.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the plasmodium is P vivax.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the plasmodium is administrated at an amount of not less than 100 plasmodium infected red blood cells or not less than 5 plasmodium sporozoites.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the method further comprises administering to the patient a pharmaceutically acceptable adjuvant.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the adjuvant is any one or a combination of at least two of an excipient, a diluent, a carrier, a flavoring agent, a binder and a filler.
